GDTC CytoMed Therapeutics Ltd IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1873093 · Reporting currency SGD · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: SGD | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 324,387 | 69,501 | — | — | — |
| R&D expense | 2.22M | 1.91M | 1.59M | 1.52M | 1.09M |
| Interest expense | 20,906 | 20,313 | 51,282 | 125,175 | 117,696 |
| Pretax income | -4.00M | -2.52M | -4.13M | -3.13M | -2.05M |
| Income tax | — | — | 653 | 1,640 | — |
| Net income | -3.98M | -2.52M | -4.13M | -3.13M | -2.05M |
| EPS (basic) | -0.34 | -0.22 | -0.39 | -0.40 | -0.30 |
| EPS (diluted) | -0.34 | -0.22 | -0.39 | -0.40 | -0.30 |
| Weighted avg. shares (diluted) | 11.65M | 11.54M | 10.63M | 7.92M | 6.93M |
| Balance sheet | |||||
| Cash & equivalents | 2.10M | 4.70M | 6.22M | 1.58M | 2.51M |
| Short-term investments | — | — | 43,080 | — | — |
| Receivables | 1.57M | 1.03M | 1.10M | 914,144 | 768,975 |
| Current assets | 3.66M | 6.00M | 10.10M | 2.49M | 3.28M |
| PP&E, netmay include right-of-use assets (IFRS) | 3.69M | 3.25M | 2.06M | 2.47M | 2.50M |
| Goodwill | 355 | 355 | 355 | 355 | 355 |
| Intangibles | 124,894 | 93,050 | 12,413 | 18,809 | 32,023 |
| Total assets | 7.98M | 10.07M | 12.37M | 5.23M | 6.08M |
| Current liabilities | 709,169 | 606,622 | 716,943 | 4.17M | 2.94M |
| Short-term debt | 40,847 | 37,650 | 33,926 | 334,779 | 385,691 |
| Long-term debt | 368,656 | 394,310 | 407,772 | 468,827 | 539,119 |
| Total debt | 409,503 | 431,960 | 441,698 | 803,606 | 924,810 |
| Total liabilities | 1.13M | 1.02M | 1.12M | 4.64M | 3.49M |
| Shareholders' equity | 6.54M | 8.97M | 11.25M | 586,980 | 2.59M |
| Net debt | -1.69M | -4.27M | -5.78M | -776,112 | -1.59M |
| Shares outstanding | 11.83M | 11.54M | 11.53M | 8.44M | 7.48M |
| Cash flow statement | |||||
| Operating cash flow | -3.70M | -2.71M | -3.53M | -1.40M | -1.71M |
| Capital expenditure | 637,850 | 1.40M | 58,295 | 473,795 | 582,354 |
| Free cash flow | -4.34M | -4.11M | -3.59M | -1.87M | -2.30M |
| Investing cash flow | 929,283 | 1.13M | -2.73M | -473,305 | -823,666 |
| Financing cash flow | 208,648 | -64,892 | 10.92M | 968,716 | 4.17M |
| Depreciation & amortization | 371,042 | 322,164 | 374,752 | 379,667 | 316,666 |
| Stock-based compensation | 694,200 | — | — | — | — |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, SGD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.